Updates in the Management of Small-Cell Lung Cancer in the Second-Line and Beyond

Balazs Halmos, MD, discusses the safety and efficacy of lurbinectedin in the second-line setting for patients with small cell lung cancer.

Nagashree Seetharamu, MD, MBBS, discusses interpreting the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology and deciding when to initiate hospice care in patients with small cell lung cancer.

Fred R. Hirsch, MD, PhD, discusses the rarity of diagnosing small cell lung cancer early in the disease course, unmet needs in SCLC screening, the importance of ECOG performance score when considering patients for clinical trials, and factors influencing hospice care decisions in patients with SCLC.